Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara®, over three medication cycles

European Journal of Contraception and Reproductive Health Care

Volumn 13, Issue 1, 2008, Pages 39-48

  Spona, J ^a,d   Binder, N ^b   Hoschen K ^b   Feichtinger, W ^c  

^a Vitalogic   (Austria)

^b GRÜNENTHAL GMBH   (Germany)

^c Institute for Sterility Treatment   (Austria)

^d NONE   (Austria)

Author keywords

Belara ; Contraception; Cycle stability; Efficacy; Ethinyl oestradiol chlormadinone acetate; Ovarian activity; Safety

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; APPENDICITIS; ARTICLE; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; COMMON COLD; CONCEPTION; CONTRACEPTION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; ECHOGRAPHY; FATIGUE; FEMALE; FERTILIZATION; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MASTALGIA; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NIDATION; NORMAL HUMAN; OUTCOME ASSESSMENT; OVARY FUNCTION; OVULATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SPOTTING; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; CERVIX UTERI; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL, COMBINED; ENDOMETRIUM; ETHINYL ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HUMANS; OVARY;

EID: 39449105175     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180701619247     Document Type: Article

References (22)

1. van Heusden AM, Fauser BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of lowdose combined oral contraceptives. Contraception 1999;59:237-43.
2. Benagiano G, Bastianelli C, Farris M. Contraception today. Ann NY Acad Sci 2006;1092:1-32.
3. van der Does J, Exalto N, Dieben T, Bennink HC. Ovarian activity suppression by two different low-dose triphasic oral contraceptives. Contraception 1995;52:357-61.
4. van Heusden AM, Fauser BC. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002;8:345-58.
5. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception 1993;47:583-90.
6. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188-215.
7. Kuhl H. Ideal dose of ethinylestradiol. In: Elstein M, ed. Extragenital effects of oral contraceptives. New York: The Parthenon Publishing Group; 1997. pp 27-38.
8. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: Efficacy, tolerability and anti-androgenic properties. Contraception 2003;67:305-12.
9. Bitzer J. Belara - proven benefits in daily practice. Eur J Contracept Reprod Health Care 2005;10 Suppl 1:19-25.
10. Spona J, Feichtinger W, Kindermann C, et al. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00 mg dienogest on the hemostatic system. Contraception 1997;56:67-75.
11. Spona J, Feichtinger W, Kindermann C, et al. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception 1996;54:299-304.
12. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999;72:115-20.
13. Hackeloer BJ, Robinson HP. Ultrasound examination of the growing ovarian follicle and of the corpus luteum during the normal physiologic menstrual cycle. Geburtshilfe Frauenheilkd 1978;38:163-8.
14. Wetzels LC, Hoogland HJ. Relation between ultrasonographic evidence of ovulation and hormonal parameters: Luteinizing hormone surge and initial progesterone rise. Fertil Steril 1982;37:336-41.
15. Insler V, Glezerman M, Bernstein D. Diagnosis and treatment of the cervical factor of infertility. Reproduction 1981;5:295-300.
16. Insler V, Melmed H, Eichenbrenner I, et al. The cervical score, a simple semiquantative method for monitoring of the menstrual cycle. Int J Gynecol Obstet 1972;10:223-8.
17. Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001;203:38-44.
18. Zahradnik HP. Belara - a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care 2005;10 Suppl 1:12-18.
19. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 1998;57:103-9.
20. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Invest 2002;22:221-31.
21. Archer DF, Maheux R, DelConte A, O'Brien FB. A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contraception 1997;55:139-44.
22. Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 1995;51:3-12.